Vernalis, Paul Capital Partners deal

Vernalis will repurchase full rights to the royalty stream for frovatriptan from Paul Capital's Paul Capital Healthcare fund for $32.6 million in cash. In 2008, Paul Capital paid €18.4 million ($29.1 ...